Stephen Knight, M.D. Board Member
Stephen Knight joined F-Prime Capital, where he serves as President and Managing Partner, in 2003. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve serves on the Board of Directors of Innovent Biologics, Iora Health, Pulmocide, and Semma Therapeutics. Steve previously served on the boards of several private and public health care companies including Blueprint Medicines (BPMC), Denali Therapeutics (DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Ironwood Pharmaceuticals (IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Proteostasis Therapeutics (PTI), and Respivert, Ltd (acquired by J&J).
Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He was also a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management, and received a B.S. in biology from Columbia University, where he graduated summa cum laude and Phi Beta Kappa.